Trials / Completed
CompletedNCT03786484
Study of PBF-999 in Solid Tumour Advanced Cancer
Phase I/Ib Trial of Single Agent PBF-999 in Solid Tumour Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Palobiofarma SL · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Multicentric phase I (dose escalation plus expansion) clinical trial of PBF-999 in patients with immunotherapy naïve and pretreated solid tumors to evaluate the safety, tolerability and preliminary efficacy of the compound
Detailed description
The phase I dose escalations will be conducted utilizing the standard 3+3 dose escalation method. Pharmacokinetic (PK) data will be obtained for PBF-999. The phase I dose expansion will consist of 1 group including immunotherapy naïve and pretreated (previous immune checkpoint inhibitors; anti-CTLA-4, anti-PD-1, anti-PD-L1 and/or combinations) solid tumors cancer patients. Pharmacodynamic (PD) data will be obtained for potential biomarker analysis with pre-treatment and on-treatment tumor biopsies. Phase I Dose Escalation (3+3 Design): 1\. The MTD will be defined as the highest dose level at which less than 2 out of 6 patients (\<33%) experience DLT in Cycle 1 (first 28 days). Phase I Safety Expansion Once RP2D has been declared for PBF-999 using the standard 3+3 design, up to 20 additional solid tumor cancer patients may be treated at the RP2D to further explore safety and tolerability of the selected PBF-999 dose. Patients in this study will be males or females 18 years of age or older. Patients must have histologically or cytologically confirmed cancer with at least one measurable lesion, with adequate organ and marrow function, and with ECOG performance status of 0-1. Eligible patients must have received at least one prior line of therapy for their disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PBF-999 | Phosphodiesterase 10 inhibitor (PDE10i) |
Timeline
- Start date
- 2017-10-01
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
- First posted
- 2018-12-26
- Last updated
- 2023-01-26
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT03786484. Inclusion in this directory is not an endorsement.